In vivo experimental approach for the risk assessment of fluoroquinolone antibacterial agents-induced long QT syndrome.
D000284:Administration, Oral; D000818:Animals; D001372:Aza Compounds / Q000008:administration & dosage / Q000009:adverse effects*; D001794:Blood Pressure / Q000187:drug effects; D002698:Chloralose; D004195:Disease Models, Animal; D004285:Dogs; D004562:Electrocardiography; D005260:Female; D024841:Fluoroquinolones / Q000008:administration & dosage / Q000009:adverse effects*; D000077734:Gatifloxacin; D006221:Halothane; D006327:Heart Block / Q000209:etiology / Q000503:physiopathology; D006339:Heart Rate / Q000187:drug effects; D007262:Infusions, Intravenous; D008133:Long QT Syndrome / Q000139:chemically induced* / Q000503:physiopathology; D008297:Male; D000077266:Moxifloxacin; D011804:Quinolines / Q000008:administration & dosage / Q000009:adverse effects*; D011817:Rabbits; D018570:Risk Assessment; D013997:Time Factors; D016171:Torsades de Pointes / Q000139:chemically induced / Q000503:physiopathology; D016277:Ventricular Function, Left / Q000187:drug effects
D001372:Aza Compounds; D024841:Fluoroquinolones; D011804:Quinolines; D002698:Chloralose; C076246:sitafloxacin; D000077734:Gatifloxacin; D000077266:Moxifloxacin; D006221:Halothane